{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T22:18:12Z","timestamp":1773872292570,"version":"3.50.1"},"reference-count":65,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009533","name":"Armenian National Science and Education Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009533","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Medical Research"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.arcmed.2019.12.011","type":"journal-article","created":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T13:33:16Z","timestamp":1582032796000},"page":"13-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Association of Genetic Variants of Dopamine and Serotonin In Schizophrenia"],"prefix":"10.1016","volume":"51","author":[{"given":"Roksana","family":"Zakharyan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hovsep","family":"Ghazaryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lenka","family":"Kocourkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andranik","family":"Chavushyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Artur","family":"Mkrtchyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronika","family":"Zizkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arsen","family":"Arakelyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Petrek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcmed.2019.12.011_bib1","doi-asserted-by":"crossref","first-page":"555","DOI":"10.31887\/DCNS.2014.16.4\/jpouget","article-title":"Pharmacogenetics and outcome with antipsychotic drugs","volume":"16","author":"Pouget","year":"2014","journal-title":"Dialogues Clin Neurosci"},{"key":"10.1016\/j.arcmed.2019.12.011_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2013.06.035","article-title":"CYP450 pharmacogenetic treatment strategies for antipsychotics: a review of the evidence","volume":"149","author":"Ravyn","year":"2013","journal-title":"Schizophr Res"},{"key":"10.1016\/j.arcmed.2019.12.011_bib3","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.schres.2007.06.014","article-title":"COMT Val158Met polymorphism predicts negative symptoms response to treatment with olanzapine in schizophrenia","volume":"95","author":"Bertolino","year":"2007","journal-title":"Schizophr Res"},{"key":"10.1016\/j.arcmed.2019.12.011_bib4","first-page":"47","article-title":"Successful use of olanzapine in adolescent monozygotic twins with catatonic schizophrenia resistant to electroconvulsive therapy: case report","volume":"29","author":"Dudova","year":"2008","journal-title":"Neuro Endocrinol Lett"},{"key":"10.1016\/j.arcmed.2019.12.011_bib5","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2019.12.011_bib6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.coph.2011.02.007","article-title":"The role of serotonin receptors in the action of atypical antipsychotic drugs","volume":"11","author":"Meltzer","year":"2011","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.arcmed.2019.12.011_bib7","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/YPG.0b013e32834371a7","article-title":"COMT (Val(158\/108)Met) genotype moderates the impact of antipsychotic medication on verbal IQ in twins with schizophrenia","volume":"21","author":"Rebollo-Mesa","year":"2011","journal-title":"Psychiatr Genet"},{"key":"10.1016\/j.arcmed.2019.12.011_bib8","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.drudis.2007.07.018","article-title":"The impact of pharmacogenetics on the development and use of antipsychotic drugs","volume":"12","author":"Reynolds","year":"2007","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.arcmed.2019.12.011_bib9","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.neulet.2007.02.076","article-title":"Influence of catechol-O-methyltransferase Val158Met polymorphism on neuropsychological and functional outcomes of classical rehabilitation and cognitive remediation in schizophrenia","volume":"417","author":"Bosia","year":"2007","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.arcmed.2019.12.011_bib10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.psychres.2014.02.015","article-title":"Factors affecting cognitive remediation response in schizophrenia: the role of COMT gene and antipsychotic treatment","volume":"217","author":"Bosia","year":"2014","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.arcmed.2019.12.011_bib11","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1503\/jpn.120178","article-title":"COMT, neuropsychological function and brain structure in schizophrenia: a systematic review and neurobiological interpretation","volume":"38","author":"Ira","year":"2013","journal-title":"J Psychiatry Neurosci"},{"key":"10.1016\/j.arcmed.2019.12.011_bib12","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/ajmg.b.30352","article-title":"Lack of influence of COMT and NET genes variants on executive functions in schizophrenic and bipolar patients, their first-degree relatives and controls","volume":"141B","author":"Szoke","year":"2006","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"10.1016\/j.arcmed.2019.12.011_bib13","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.euroneuro.2004.07.001","article-title":"Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response","volume":"15","author":"Reynolds","year":"2005","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.arcmed.2019.12.011_bib14","doi-asserted-by":"crossref","first-page":"24663","DOI":"10.3402\/tdp.v2.24663","article-title":"Genetics of antipsychotic drug outcome and implications for the clinician: into the limelight","volume":"2","author":"Changasi","year":"2014","journal-title":"Transl Dev Psychiatry"},{"key":"10.1016\/j.arcmed.2019.12.011_bib15","series-title":"The international statistical classification of diseases and related health problems","author":"Organization","year":"1992"},{"key":"10.1016\/j.arcmed.2019.12.011_bib16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ajp.2014.08.002","article-title":"Antipsychotic treatment of schizophrenia: an update","volume":"11","author":"Bruijnzeel","year":"2014","journal-title":"Asian J Psychiatr"},{"key":"10.1016\/j.arcmed.2019.12.011_bib17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1517\/17425255.2011.532787","article-title":"Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction","volume":"7","author":"Zhang","year":"2011","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.arcmed.2019.12.011_bib18","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/ejhg.2015.206","article-title":"Genetic evidence for an origin of the Armenians from Bronze Age mixing of multiple populations","volume":"24","author":"Haber","year":"2016","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.arcmed.2019.12.011_bib19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/cpp.693","article-title":"Inter-rater reliability of the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID I) and Axis II Disorders (SCID II)","volume":"18","author":"Lobbestael","year":"2011","journal-title":"Clin Psychol Psychother"},{"key":"10.1016\/j.arcmed.2019.12.011_bib20","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/JCP.0000000000000294","article-title":"DRD2 genotypic and haplotype variation is associated with improvements in negative symptoms after 6 weeks' amisulpride treatment","volume":"35","author":"Kang","year":"2015","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.arcmed.2019.12.011_bib21","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3389\/fimmu.2015.00476","article-title":"A dataset of 26 candidate gene and pro-inflammatory cytokine variants for association studies in idiopathic pulmonary fibrosis: frequency distribution in normal Czech population","volume":"6","author":"Kishore","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.arcmed.2019.12.011_bib22","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1086\/519795","article-title":"PLINK: a toolset for whole-genome association and population-based linkage analysis","volume":"81","author":"Purcell","year":"2007","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.arcmed.2019.12.011_bib23","series-title":"genpwr: Power calculations under genetic model misspecification. R package version 1.0.1","author":"Moore","year":"2019"},{"key":"10.1016\/j.arcmed.2019.12.011_bib24","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.biopsych.2009.08.040","article-title":"Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs","volume":"67","author":"Andreasen","year":"2010","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.arcmed.2019.12.011_bib25","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2217\/pgs.10.182","article-title":"Gene-gene interaction analyses between NMDA receptor subunit and dopamine receptor gene variants and clozapine response","volume":"12","author":"Hwang","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.arcmed.2019.12.011_bib26","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/tpj.2009.63","article-title":"Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions","volume":"10","author":"Correia","year":"2010","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.arcmed.2019.12.011_bib27","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/tpj.2013.23","article-title":"Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders","volume":"14","author":"McCracken","year":"2014","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.arcmed.2019.12.011_bib28","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/hup.930","article-title":"Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder","volume":"23","author":"Adams","year":"2008","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.arcmed.2019.12.011_bib29","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/tpj.2016.79","article-title":"Association between DRD2 and DRD3 gene polymorphisms and gastrointestinal symptoms induced by levodopa therapy in Parkinson's disease","volume":"18","author":"Rieck","year":"2018","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.arcmed.2019.12.011_bib30","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00228-009-0658-z","article-title":"Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson's disease patients","volume":"65","author":"Liu","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.arcmed.2019.12.011_bib31","first-page":"127","article-title":"Genetic polymorphisms in dopaminergic system and treatment-resistant schizophrenia","volume":"28","author":"Terzic","year":"2016","journal-title":"Psychiatr Danub"},{"key":"10.1016\/j.arcmed.2019.12.011_bib32","first-page":"47","article-title":"The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue","volume":"5","author":"Brisch","year":"2014","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.arcmed.2019.12.011_bib33","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11920-007-0041-7","article-title":"Dopamine hypothesis of schizophrenia: making sense of it all","volume":"9","author":"Toda","year":"2007","journal-title":"Curr Psychiatry Rep"},{"key":"10.1016\/j.arcmed.2019.12.011_bib34","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1126\/science.1145194","article-title":"Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons","volume":"188","author":"Seeman","year":"1975","journal-title":"Science"},{"key":"10.1016\/j.arcmed.2019.12.011_bib35","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/0964704X.2012.664087","article-title":"The chlorpromazine enigma","volume":"22","author":"Baumeister","year":"2013","journal-title":"J Hist Neurosci"},{"key":"10.1016\/j.arcmed.2019.12.011_bib36","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/oxfordjournals.schbul.a033325","article-title":"Dysfunctions in multiple interrelated systems as the neurobiological bases of schizophrenic symptom clusters","volume":"24","author":"O\u2019Donnell","year":"1998","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.arcmed.2019.12.011_bib37","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3389\/fnhum.2014.00216","article-title":"Association of COMT and COMT-DRD2 interaction with creative potential","volume":"8","author":"Zhang","year":"2014","journal-title":"Front Hum Neurosci"},{"key":"10.1016\/j.arcmed.2019.12.011_bib38","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/FPC.0b013e3283397d06","article-title":"Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment","volume":"20","author":"Hong","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.arcmed.2019.12.011_bib39","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/tpj.2010.65","article-title":"Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain","volume":"12","author":"Muller","year":"2012","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.arcmed.2019.12.011_bib40","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ajp.2017.07.026","article-title":"Identification of genetic correlates of response to risperidone: findings of a multicentric schizophrenia study from India","volume":"29","author":"Kaur","year":"2017","journal-title":"Asian J Psychiatr"},{"key":"10.1016\/j.arcmed.2019.12.011_bib41","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3371\/1935-1232-11.1.39","article-title":"Genetic variation of the Mu opioid receptor (OPRM1) and dopamine D2 receptor (DRD2) is related to smoking differences in patients with schizophrenia but not bipolar disorder","volume":"11","author":"Hirasawa-Fujita","year":"2017","journal-title":"Clin Schizophr Relat Psychoses"},{"key":"10.1016\/j.arcmed.2019.12.011_bib42","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/0022-3468(95)90494-8","article-title":"Failure to detect dopaminergic neuroblastoma in a mass-screening system","volume":"30","author":"Naito","year":"1995","journal-title":"J Pediatr Surg"},{"key":"10.1016\/j.arcmed.2019.12.011_bib43","doi-asserted-by":"crossref","first-page":"28","DOI":"10.4103\/jpp.JPP_197_16","article-title":"Risperidone-induced adverse drug reactions and role of DRD2 (-141 C Ins\/Del) and 5HTR2C (-759 C>T) genetic polymorphisms in patients with schizophrenia","volume":"8","author":"Alladi","year":"2017","journal-title":"J Pharmacol Pharmacother"},{"key":"10.1016\/j.arcmed.2019.12.011_bib44","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/fcp.12424","article-title":"Dopamine (DRD2) and serotonin (HTR2A, 2C) receptor gene polymorphisms do not influence early response to risperidone in South Indian patients with schizophrenia","volume":"33","author":"Alladi","year":"2019","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.arcmed.2019.12.011_bib45","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.schres.2017.03.014","article-title":"The impacts of dopamine D2 receptor polymorphism and antipsychotic dosage on dopamine supersensitivity psychosis in schizophrenia","volume":"190","author":"Takase","year":"2017","journal-title":"Schizophr Res"},{"key":"10.1016\/j.arcmed.2019.12.011_bib46","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.neubiorev.2017.01.006","article-title":"The DRD2 rs1076560 polymorphism and schizophrenia-related intermediate phenotypes: A systematic review and meta-analysis","volume":"74","author":"Luykx","year":"2017","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.arcmed.2019.12.011_bib47","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/jnr.23180","article-title":"HTR2A-1438A\/G polymorphism influences the risk of schizophrenia but not bipolar disorder or major depressive disorder: a meta-analysis","volume":"91","author":"Gu","year":"2013","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.arcmed.2019.12.011_bib48","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/ajmg.b.32248","article-title":"Association of the T102C polymorphism in the HTR2A gene with major depressive disorder, bipolar disorder, and schizophrenia","volume":"165B","author":"Tan","year":"2014","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"10.1016\/j.arcmed.2019.12.011_bib49","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1017\/neu.2013.22","article-title":"Association of schizophrenia with T102C (rs6313) and 1438 A\/G (rs6311) polymorphisms of HTR2A gene","volume":"25","author":"Yildiz","year":"2013","journal-title":"Acta Neuropsychiatr"},{"key":"10.1016\/j.arcmed.2019.12.011_bib50","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/sj.ejhg.5201180","article-title":"Association between schizophrenia and DRD3 or HTR2 receptor gene variants","volume":"12","author":"Baritaki","year":"2004","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.arcmed.2019.12.011_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/jpm6010009","article-title":"Serotonin 2A receptor SNP rs7330461 association with treatment response to pomaglumetad methionil in patients with schizophrenia","volume":"6","author":"Nisenbaum","year":"2016","journal-title":"J Pers Med"},{"key":"10.1016\/j.arcmed.2019.12.011_bib52","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/tpj.2016.44","article-title":"Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes","volume":"16","author":"Mas","year":"2016","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.arcmed.2019.12.011_bib53","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/S1734-1140(13)71476-2","article-title":"BDNF rs 6265 polymorphism and COMT rs 4680 polymorphism in deficit schizophrenia in Polish sample","volume":"65","author":"Pelka-Wysiecka","year":"2013","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.arcmed.2019.12.011_bib54","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/FPC.0000000000000314","article-title":"Gene-gene interaction between DRD4 and COMT modulates clinical response to clozapine in treatment-resistant schizophrenia","volume":"28","author":"Rajagopal","year":"2018","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.arcmed.2019.12.011_bib55","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s10517-016-3250-4","article-title":"CYP1A2 and CYP2D6 gene polymorphisms in schizophrenic patients with neuroleptic drug-induced side effects","volume":"160","author":"Ivanova","year":"2016","journal-title":"Bull Exp Biol Med"},{"key":"10.1016\/j.arcmed.2019.12.011_bib56","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0920-9964(00)00187-0","article-title":"Duration of untreated psychosis as a predictor of outcome in first-episode schizophrenia: a retrospective study","volume":"52","author":"Altamura","year":"2001","journal-title":"Schizophr Res"},{"key":"10.1016\/j.arcmed.2019.12.011_bib57","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eurpsy.2011.11.001","article-title":"Predictors of short- and long-term clinical outcome in schizophrenic psychosis: the Northern Finland 1966 Birth Cohort study","volume":"28","author":"Juola","year":"2013","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.arcmed.2019.12.011_bib58","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3109\/13651501.2010.519035","article-title":"Global assessment of psychosocial functioning and predictors of outcome in schizophrenia","volume":"15","author":"Stefanopoulou","year":"2011","journal-title":"Int J Psychiatry Clin Pract"},{"key":"10.1016\/j.arcmed.2019.12.011_bib59","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1017\/S0033291706007951","article-title":"A systematic review of longitudinal outcome studies of first-episode psychosis","volume":"36","author":"Menezes","year":"2006","journal-title":"Psychol Med"},{"key":"10.1016\/j.arcmed.2019.12.011_bib60","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.schres.2006.07.007","article-title":"A population based elaboration of the role of age of onset on the course of schizophrenia","volume":"88","author":"Rabinowitz","year":"2006","journal-title":"Schizophr Res"},{"key":"10.1016\/j.arcmed.2019.12.011_bib61","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.tins.2007.03.002","article-title":"Dopamine: 50 years in perspective","volume":"30","author":"Iversen","year":"2007","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.arcmed.2019.12.011_bib62","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/0964704X.2012.678199","article-title":"History of the discovery of the antipsychotic dopamine D2 receptor: a basis for the dopamine hypothesis of schizophrenia","volume":"22","author":"Madras","year":"2013","journal-title":"J Hist Neurosci"},{"key":"10.1016\/j.arcmed.2019.12.011_bib63","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0304-3940(96)13094-9","article-title":"Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine","volume":"217","author":"Arranz","year":"1996","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.arcmed.2019.12.011_bib64","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/sj.mp.4000348","article-title":"Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine","volume":"3","author":"Arranz","year":"1998","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.arcmed.2019.12.011_bib65","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0893-133X(98)00007-4","article-title":"Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients","volume":"19","author":"Masellis","year":"1998","journal-title":"Neuropsychopharmacology"}],"container-title":["Archives of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440919304825?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440919304825?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:48:03Z","timestamp":1759261683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0188440919304825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0188440919304825"],"URL":"https:\/\/doi.org\/10.1016\/j.arcmed.2019.12.011","relation":{},"ISSN":["0188-4409"],"issn-type":[{"value":"0188-4409","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of Genetic Variants of Dopamine and Serotonin In Schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Archives of Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcmed.2019.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 IMSS. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}